Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.55 |
| ▸ | PRKDC | P78527 | 18/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.47 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844412 | 0.73 | MTOR (0.33) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL8326897 | 0.71 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL30387566 | 0.69 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL3420175 | 0.69 | PIK3CD (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL14742662 | 0.67 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL3422985 | 0.67 | ABL1 (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL3423942 | 0.67 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL18493857 | 0.67 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL2905037 | 0.67 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL8975540 | 0.67 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102159213-B | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines | CHEMOCENTRYX INC | 2015-05-27 | — | — | CN | disclosed |
| EP-2323663-B1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8946240-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8343975-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. | 2013-01-01 | — | — | US | disclosed |
| EP-2323663-A4 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX INC (US) | 2012-05-30 | — | — | EP | disclosed |
| CN-102159213-A | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines | CHEMOCENTRYX INC | 2011-08-17 | — | — | CN | disclosed |
| EP-2323663-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | ChemoCentryx, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323663-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | ChemoCentryx, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010030815-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100069396-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010030815-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069396-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | PIK3CD 2346/4885PIK3CA 1855/4885PIK3CB 2380/4885 |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | PIK3CD 2346/4885PIK3CA 1855/4885PIK3CB 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.